ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pulmonary Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

19,715Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 568

$1.98M Total Retail Price of All Prescriptions

Rank: 4 out of 568

859 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
89% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 19,018 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

61% of this provider’s prescriptions were for brand-name drugs, compared to an average of 56%.

Prescription Price

$101 was the average price of a prescription from this provider, compared to $126 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
PROAIR HFA 1,343 1,283 10 1 5
SINGULAIR 1,223 1,139 10 2 9
ADVAIR DISKUS 1,163 1,117 3 2
SIMVASTATIN 979 960 4 3
ALENDRONATE SODIUM 951 951 5 30
FLUTICASONE PROPIONATE 940 854 6 21
SPIRIVA 862 829 7 1
AMLODIPINE BESYLATE 696 686 8 6
MONTELUKAST SODIUM 641 594 10 9 24
FLOVENT DISKUS 551 513 10 10 77
DIOVAN 546 546 11 29
EVISTA 501 501 12 67
ATENOLOL 435 421 13 25
JANUVIA 428 421 14 32
LISINOPRIL 393 393 15 12
ATORVASTATIN CALCIUM 317 315 16 15
ASTEPRO 313 281 10 17 114
ACTONEL 273 273 18 120
COMBIVENT 267 257 19 28
FLOVENT HFA 263 252 20 43
NASONEX 251 239 21 49
ALLOPURINOL 244 235 22 71
METFORMIN HCL 238 236 23 13
VENTOLIN HFA 237 223 24 16
METOPROLOL SUCCINATE 225 225 25 18
DIOVAN HCT 220 220 26 45
OMEPRAZOLE 209 199 27 8
AZELASTINE HCL 209 192 27 113
ACTOS 193 191 29 115
THEOPHYLLINE ANHYDROUS 168 168 30 48
LEVOFLOXACIN 156 149 31 53
CELEBREX 118 118 32 146
SYMBICORT 117 117 33 7
AZITHROMYCIN 109 107 34 17
LEVOTHYROXINE SODIUM 100 100 35 10
NEXIUM 100 96 35 27
TAMSULOSIN HCL 90 90 37 35
LOSARTAN POTASSIUM 89 79 38 23
ISONIAZID 89 85 10 38 164
PATADAY 86 76 40 200
THEO-24 81 81 41 197
METFORMIN HCL ER 79 72 42 62
PREDNISONE 78 70 43 4
TRICOR 73 65 44 160
CALCITONIN-SALMON 71 71 45 196
XOPENEX HFA 69 69 46 124
LIPITOR 68 68 47 50
CLOPIDOGREL 65 65 48 38
QVAR 63 61 49 40
PIOGLITAZONE HCL 62 62 R 50 259
AVODART 59 59 51 149
ZOLPIDEM TARTRATE 59 59 51 20
PROVENTIL HFA 58 51 53 64
METOPROLOL TARTRATE 58 58 53 14
FEXOFENADINE HCL 56 54 55 214
PLAVIX 51 49 56 44
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 4, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.